Merck & Co

Receive alerts
Market Cap:
$217.79 billion
52 weeks high
52 weeks low

Viewing results 1-25 of 104


Hemispherx Biopharma says FDA authorizes study using aspirin and flagship drug ampligen to treat prostate cancer

The Phase 2 study will be carried out at the Roswell Park Comprehensive Cancer Center in Buffalo and involve up to 60 patients...

on 13/5/19

Hemispherx sees potential commercialization of flagship drug ampligen for Chronic Fatigue Syndrome

The company said results of a recent Stanford University diagnostic test of 20 patients with MF/CFS were 'impressive'...

on 6/5/19

AstraZeneca granted Breakthrough Therapy Designation for rare genetic condition treatment

A breakthrough therapy designation is designed to expedite the development and review of medicines that are intended to treat a serious condition and have shown promise in early-stage clinical trials...

on 1/4/19

Hemispherx Biopharma takes cancer war to new stage with drug Ampligen

A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen...

on 8/3/19

CytoDyn presses forward with HIV treatment after Phase 3

Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use...

on 6/3/19

Hemispherx announces start of Merck-supported ovarian cancer clinical drug trial

Last month, tests started for combination therapy targeting metastatic, triple-negative breast cancer...

on 11/2/19

ROBO Global says 3D printing poised for a high-growth, ‘profitable future’

A senior research analyst at Robo Global writes that with major industries investing heavily in 3D printing, the sector is a ‘key area of focus’ for investors in the robotics, automation and artificial intelligence space...

on 4/2/19

CytoDyn says it’s on the cusp of a breakthrough HIV treatment after Phase 3 trial

Leronlimab shows promise as an antiviral agent with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use...

on 30/1/19

Moderna is biggest biotech IPO, draws $604 million despite turbulent market

The Cambridge biotech, which is developing novel messenger RNA technology, priced at the midpoint of expected range in a sign of resiliency but shares declined in their first few minutes of trading...

on 7/12/18

Moderna Therapeutics on path to becoming biggest US biotech IPO in history

The Cambridge biotech, which is developing novel messenger RNA technology, plans to raise up to $600 million...

on 6/12/18

Biotech companies dominate at Dawson James Securities Small Cap Growth Conference

Interpace Diagnostics, Hemispherx Biopharma among the standouts presenting at the investor-focused event...

on 1/11/18

Dynavax Technologies shares climb after drug test to treat melanoma shows positive response rate

The company's lead drug, SD-101 is being evaluated for its safety and activity...

on 22/10/18

Syndax's Entinostat in combination with Keytruda fails to meet endpoint in mid-stage trial for lung cancer

The Massachusetts biotech earlier demonstrated that Entinostat in combination with hormone therapy results in better overall survival rates in breast cancer patients...

on 25/9/18

IPO Roundup: Urovant Sciences, EdtechX and Remora Royalty to tap the capital markets, while Volvo Cars drops IPO

All eyes are on hedge-funder-turned-biotech whiz kid Vivek Ramaswamy who is launching his fifth biotech company Urovant Sciences...

on 11/9/18

IPO Roundup: Search software company Elastic to raise US$100mln as competition with Amazon heats up

The California-based company’s Elasticsearch open-source software is used by customers like Uber, Walgreens, Adobe Systems, Merck and Sprint ...

on 5/9/18

Oppenheimer reiterates Outperform rating on BioLineRx after positive data from GENISIS study of BL-8040

Meanwhile, Maxim was also pleased with the study of BL-8040 as a stem cell mobilizer for bone marrow transplants moving ahead of schedule ...

on 7/8/18

BioLineRx's collaboration with Merck supports the potential of BL-8040 in ‘difficult to treat cancers,’ says Maxim

The BL-8084 platform continues to make progress across multiple indications and data from several studies is expected in 2018...

on 31/7/18

Merck's 2Q earnings beat Street with sales turbocharged by cancer drug Keytruda

Drug giant raised its full-year guidance to a range of US$4.22 and US$4.30 a share compared with US$4.16 to US$4.28 a share expected last quarter...

on 27/7/18

Bristol-Myers Squibb's 2Q earnings beat Street on healthy sales of its blockbuster cancer drug Opdivo

The drugmaker raised its full-year forecast to between US$3.55 and US$3.65 per share, taking up the top and bottom end of its previous forecast by US$0.20 per share...

on 26/7/18

Two of AstraZeneca’s key cancer drugs win speedy approvals in Japan

Lynparza and Imfinzi are likely to play an important role if AstraZeneca is to hit its target of generating annual sales of US$45bn by 2023...

on 2/7/18

AstraZeneca’s Lynparza drug sails through late-stage ovarian cancer study

The drug has already been approved for later use in ovarian and breast cancer patients, but the SOLO-1 trial has sowed it could be useful as a first-line treatment...

on 27/6/18

AstraZeneca and Eli Lilly halt late-stage Alzheimer’s study as drug shows no sign of working

AstraZeneca and Lilly’s lanabecestat drug can be added to the list of failed Alzheimer’s treatments; in fact, 99% of all drugs developed to treat the disease have failed clinical trials in the past ten years...

on 12/6/18

AstraZeneca and Merck present data from prostate cancer trial at ASCO 2018

The data showed that the combination of Lynparza and abiraterone can help patients with a specific form of prostate cancer to live for longer without their disease getting worse...

on 5/6/18